OncoCyte

OncoCyte Corporation is a biotechnology company dedicated to the development and commercialization of innovative, non-invasive diagnostics for early cancer detection. Founded in 2009 and headquartered in Irvine, California, the company specializes in laboratory-developed tests, including DetermaRx, a molecular test for early-stage adenocarcinoma of the lung, and DetermaIO, a gene expression-based test. It also focuses on DetermaDx, a blood-based test for lung cancer detection, and is working on diagnostics for bladder and breast cancers. OncoCyte aims to provide actionable insights to healthcare providers and patients, enhancing decision-making in cancer care while striving to improve patient outcomes and lower healthcare costs. The company has formed strategic collaborations to facilitate comprehensive solutions for pharmaceutical clients, encompassing patient recruitment and regulatory approvals.